Verastem (VSTM) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verastem (VSTM) has outperformed Wave Life Sciences (WVE) over the past year, losing 9.3% versus a loss of 52.8%. Over five years, WVE leads with a -32.6% price change compared with -75.5% for VSTM. Verastem is the larger company by market cap ($734.5 million vs $683.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VSTM | WVE |
|---|---|---|
| Share price | $8.11 | $3.47 |
| Market cap | $734.47M | $683.76M |
| 1-day change | -1.88% | -1.98% |
| YTD return | +5.05% | -79.59% |
| 1-year return | -9.28% | -52.79% |
| 5-year return | -75.51% | -32.62% |
| EPS (TTM) | $-2.45 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.82 | $21.73 |
| 52-week low | $3.43 | $3.37 |
| Distance from 52-week high | -25.05% | -84.03% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +84.96% | +420.46% |
| Average volume | 2.25M | 3.10M |
| Shares outstanding | 90.56M | 197.05M |
| Employees | 102 | 317 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VSTM has outperformed WVE by 43.5 percentage points over the past year.
- The two companies sit in different sectors: Verastem in Healthcare and Wave Life Sciences in Health Care.
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
VSTM vs WVE FAQ
Which is bigger, Verastem or Wave Life Sciences?
Verastem (VSTM) is larger, with a market capitalization of $734.47M compared with $683.76M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, VSTM or WVE?
VSTM returned -9.28% over the past 12 months, compared with -52.79% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Verastem and Wave Life Sciences in the same industry?
No. Verastem is in the Healthcare sector, while Wave Life Sciences is in Health Care.